Long-Term Effects of Intravenous 1α(OH)D3 Combined with CaCO3 and Low-Calcium Dialysis on Secondary Hyperparathyroidism and Biochemical Bone Markers in Patients on Chronic Hemodialysis

Nephron

Volumn 74, Issue 1, 1996, Pages 89-103

  Brandi, L ^a   Daugaard, H ^a   Nielsen, P K ^a   Jensen, L T ^a   Egsmose, C ^a   Olgaard, K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

1 alpha; Hydroxycholecalciferol; Biochemical bone markers; Calcitriol; Calcium; Dialysis solution; Hemodialysis; Hyperparathyroidism; Intravenous; Parathyroid hormone; Secondary

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM CARBONATE; HYDROXYCOLECALCIFEROL; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN;

ARTICLE; BLOOD SAMPLING; BONE LESION; BONE MINERAL; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMUR NECK; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ADULT; ALKALINE PHOSPHATASE; ALUMINUM; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIUM; CALCIUM CARBONATE; CHRONIC DISEASE; DIALYSIS SOLUTIONS; DIAPHYSES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PHOSPHATES; PHOSPHORUS; PROCOLLAGEN; RENAL DIALYSIS;

EID: 0029783618     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189286     Document Type: Article

References (60)

1. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-236.
2. Cobum JW: Use of oral and parenteral ealci-triol in the treatment of renal osteodystrophy. Kidney Int 1990;38(suppl 29):54-61.
3. Madsen S. Olgaard K: Long-term trial of la-hydroxvcholccalcifcro! in adults with chronic renal failure. Eur J Clin Pharmacol 1978:13: 401-408.
4. Brandi L. Daugaard U, Tvedcgaard E. Nielsen PK. Egsmose C. Storm T. Olgaard K: Longterm suppression of secondary hyperparathyroidism by la(OH)D3 intravenously in patients on chronic hemodialysis. Am J Nephrol 1992; 12:311-318.
5. Fischer ER. Harris DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993:40:216-220.
6. Quarles D. Yohay DA. Carroll BA, Spritzer CE. Minda SA. Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994:45:1710-1721.
7. Reichel H. Szabo A. tJhl J. Pesian S. Schmutz A. Schmidt-Gayk H. Ritz E: Intermittent versus continuous administration of 1.,25-dihy-droxvvitamin Dj in experimental renal hyperparathyroidism. Kidney Int 1993:44:1259-1265.
8. Pocottc SL. Ehrenstein G. Fitzpatrick LA: Regulation of parathyroid hormone secretion. En-docrRcv 1991;12:291-301.
9. Brown EM, Brennan MF, Hurwitz S. Windcck R. Marx S. Spiegel AM. Koehler JO. Gardner DG. Aurbach GD: Dispersed cells prepared from human parathyroid glands: Distinct calcium sensitivity of adenomas vs primary hyperplasia. J Clin Endocrinol Mctab 1978:46: 267-275.
10. Brown EM. Wilkson RE, Eastman RC, Palotta J, Marynick SP: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Melab 1982:54:172-179.
11. Brent GA. LcBoff MS. Seely EW. Conlin PR. Brown EM: Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Mctab 1988:68:944-950.
12. Felscnfeld AJ, Ross D. Rodriguez M: Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease., J Am Soc Nephrol 1991;21:1136-1143.
13. Delmez JA. Tindira C. Grooms P. Dusso A. Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1.,25-dihv-droxyvitamin Dj. J Clin Invest 1989:83:1349-1355.
14. Dunlav R. Rodriguez, M. Felsenfeld AJ. Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989:36:1093-1098.
15. Cunningham J. Altmann P. Gleed JH. Butter KC, Marsh FP. O'Riordan JLH: Effect of direction and rate of change of calcium on parathyroid hormone secretion in uremia. Nephrol Dial Transplant 1989;4:339-344.
16. Kwan JTC. Beer JC, Noonan K, Cunningham J: Parathyroid sensing of the direction of change of calcium in uremia. Kidney Int 1993; 43:1104-1109.
17. Malbcrti F. Surian M, Cosci P: Improvement of secondary hyperparathyroidism and reduction of the set-point of calcium after intravenous calcitriol. Kidney Int 1993;43(suppl 41): 125-130.
18. Ali AA. Varghese Z. Moorhead JF. Baillod RA. Swcny P: Calcium set point progressively worsens in hemodialysis patients despite conventional oral la-hydroxycholecalcifcrol supplementation. Clin Nephrol 1993:39:205-209.
19. Daugaard H. Egfjord M. Olgaard K: Metabolism of intact parathyroid hormone in isolated perfused rat liver and kidney. Am J Physiol 1988;254:E740-E748.
20. Reinhardt TA. Horst RL. Orf JW. Hollis BW: A microassay for 1,25-dihydroxy vitamin D not requiring high performance liquid chromatography: Application to clinical studies. J Clin Endocrinol Metab 1984:58:91-98.
21. Egsmose C. Daugaard I I. Lund B: Determination of bone Gla protein (osteocalcin) by enzyme-linked immunosorbent assay. Clin Chim Acta 1989:184:279-288.
22. Melkko J. Niemi S. Risteli L: Radioimmunoassay of the carboxytcrminal propeptide of human type 1 procollagcn. Clin Chem 1990:36: 1328-1332.
23. Altman DG: Practical Statistics for Medical Research. London. Chapman & Hall. 1991.
24. Slatopolsky E. Weerts C. Lodpez-Hilker S. Norwood K. Zink M. Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986:315:157-161.
25. Macticr RA. Stone JV. Cox A. Stone V. Twar-dowski Z: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987;28:222-226.
26. Sawer N, Noonan K. Altman P. Marsh F. Cunningham J: High-dose calcium carbonate with step-wise reduction in dialysate calcium concentration: Effective phosphate control and aluminium avoidance in hemodialysis patients. Nephrol Dial Transplant 1989:4:105-109.
27. Slatopolsky E. Wccrts C. Norwood K. Giles K. Fryer P. Finch J. Windus D. Delmez J: Longterm effects of calcium carbonate and 2.,5 ntEq/ liter calcium dialysate on mineral metabolism. Kindey Int 1989:36:897-903.
28. Argiles A, Kerr PG. Canaud B. Flavier JL. Mior, C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993;43:630-640.
29. Spcrschncider H. Gunther K. Marzoll I. Kirchner E. Stein G: Calcium carbonate (CaCOj): An efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transplant 1993:8:530-534.
30. Rudnicki M. Hojstcd J. Petersen LJ. Sorensen HA. Hyldstrup, Transboll: Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: A randomized double-blind placebo-controlled study. Nephron 1993; 65:369-374.
31. Delmez JA. Kelber J. Tindira C. Norwood K, Giles K. Slatopolsky E: Long-term effects of early use of iv calcitriol in the prevention of secondary' hyperparathyroidism in hemodialysis patients (abstract 23 P). J Am Soc Nephrol 1993:4:695.
32. Faugere MC. Friedler RM. Malluchc HH: Efficacy and limitations of pulse i., v. And pulse oral 1.,25 vit D therapy on bone disease in patients on chronic dialysis (abstract 83 P). J Am Soc Nephrol 1993:4:695.
33. Silver J. Navch-Many T. Mayer H, Schmcizcr HJ. Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986: 78:1296-1301.
34. Pcrcz-Mijares R. Gomez-Femandcz P. Almar-cz-Jimcncz M. Ramos-Diaz M. Rivero-Bohor-qucz J: Treatment of severe hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxv-viiamin Di and dialysate with 3 mEq/l calcium concentration. Am J Nephrol 1993:13:149-154.
35. Shigcmatsu T. Kawaguchi Y. Unemura S. Yamamoto H, Momose M. Yokoyama K, Waka-bayashi Y. Ikcda M. Hasegawa T. Sakai O: Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly doses of l.,25-dihydroxycholecalcifcrol. Intern Med 1993;32:695-701.
36. Morniere PH. Esper NEL, Viron B. Judith D. Bourgeon B. Farquet CH. Ghcerbrant JD. Cha-puy MC. Orshoven AV. Pamphilc R. Fournier A: Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous la(OH)vitamin3. Oral CaCOi and low dialysate calcium. Kidney Int 1993:43(suppl 41):121-124.
37. Hercz G. Pei Y. Greenwood C. Manuel A, Sai-phoo C. Goodman WG, Serge GV. Fenton S. Sherrard DJ: Aplastic osteodystrophy without aluminum: The role of 'suppressed' parathyroid function. Kidney Int 1993:44:860-866.
38. Moriniere P. Cohen-Solal C, Belhrik S. Boudail-licz B. Marie A. Westecl PF. Renaud H, Ficvet P. Falau JD. Sebert JL. Fournier A: Disappearance of aluminic bone disease in a long-term asymptomatic dialysis population restricting AI(OH)i intake: Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989;53:93-101.
39. Goodman WG. Ramirez JA, Belin T, Gales B. Segrc GV. Salusky IB: Induction of adynamic renal osteodystrophy by intermittent calcitriol therapy in patients with secondary hyperparathyroidism (abstract). 9th Workshop on Vitamin D. Orlando 1994.
40. Kanis JA: Prevention of renal osteodystrophy by vitamin D analogs (abstract). 9th Workshop on Vitamin D. Orlando 1994.
41. Malluche HH. Monicr-Faugcre MC: The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994:4:1631-1642.
42. Sudhaker D. Goggins M. Bhat S. Rigg GA. Lester C. Szromba C: Hyperphosphatemia may blunt the parathyroid hormone (PTI I) response to intravenous calcitriol in patients with severe secondary hyperparathyroidism (HPT) of chronic hemodialysis (HD) (abstract). 9th Workshop on Vitamin D. Orlando 1994.
43. USpez-Hilker S. Dusso A. Rapp N. Martin KJ. Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990:259:F432-F443.
44. Fukushima M. Suzuki Y. Tohira Y. Nishii Y, Suzuki M. Sasaki S. Suda T: 25-Hydroxylation of la-dihydroxvvitamin Dj in vivo and in perfused rat liver. FEBS Lett 1976:65:211-214.
45. Papapoulos SE van den Berg H, Frölich M, Valenlijn RM: Circulating I.,25-dihydroxycho-lecalciferol after intravenous injections of la-livdroxycholecalciferol in patients on regular haemodialysis. Nephrol Dial Transplant 1988; 3:647-650.
46. Gallachcr SJ. Cowan RA. Fraser WD. Logue FC. Jenkins A. Boyle IT: Acute effects of intravenous In-hydroxycholccalcifcrol on parathyroid hormone, osteocalcin and calcitriol in man. Eur J Endocrinol 1994:130:141-145.
47. Brandi I. Daugaard H. Tvcdegaard E. Storm T. Olgaard K: Effects of intravenous l-alpha-hvdroxyvitamin Dj on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 1989:53:194-200.
48. Slatopolsky E. Wccrts C. Thiclan I, Horst R. Harter H. Martin KH: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxvchole-calciferol in uremic patients. J Clin Invest 1984:74:2136-2143.
49. Parfitt AM. Simon LS, Villanueva AR. Krane SM: Procollagen type 1 carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone: Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-436.
50. Hasling C. Eriksen EF, Melkko J: Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type 1 procollagen in osteoporosis. J Bone Miner Res 1991;6:1295-1299.
51. Coen G. Mazzaferro S. Ballanti P. Bonucci E. Bondatti F. Manni M. Pasquali M. Peruzza 1. Sardella D, Spurio A: Procollagen type I C-ter-mtnal extension peptide in predialysis chronic renal failure. Am, I Nephrol 1992:12:246-251.
52. Hamdy NAT. Ristcli J. Ristcli L. Harris S. Beneton MNC. Brown CB. Kanis JA: Serum type I procollagen peptide: A non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994:9:511-516.
53. Coen G. Mazzaferro S. Antoni E. Chicca S, Disanza P. Onoralo L. Spurio A. Sardella D. Trombetta M. Pasquali M: Procollagen type 1 C-tcmiinal extension peptide serum levels following parathyroidectomy in hypcrparathyroid patients. Am., I Nephrol 1994:14:106-112.
54. Bianchi ML. Colanlonio G. Montesano A. Trevisane T, Ortolani S. Rossi R. Buccianti G: Bone mass status in different degrees of chronic renal failure. Bone 1992:13:225-228.
55. Hutchison AJ. Whitehouse RW. Boulton HF. Adams JE. Mawer EB. Frecmont TJ. Gokal R: Correlation of bone histology w ith parathyroid hormone, vitamin Di and radiology in end-stagc renal disease. Kidncv Ini 1993:44:1071-1077.
56. Madsen S. Olgaard K. Ladefoged J: Bone mineral content in chronic renal failure during long-term treatment with I a-hydroxycholccal-ciferol. Acta Med Scand 1978:203:385-389.
57. Nishitani H, Yamakawa VI, Nishizawa Y. Morii H: Bone mineral loss in patients on maintenance hemodialysis with hyperphosphatemia treated with lu-hydroxycholecalciferol and calcium carbonate. J Nutr Sci Vitaminol (Tokyo) 1991;37(suppl): 113-118.
58. Ruedin P. Rizzolo R. Slosman D. Leski M. Bonjour JP: Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney hit 1994:45:245-252.
59. Fournier A. Moriniere P. Boudailliez B. Mau-rouard C. Westecl PF. Achard JM. Bouillon R. Pamphile R: Prevention of radiologically obvious hyperparathyroidism in dialysis patients with i., v. laOH vitamin Dj (one-alpha) in association with Mg(OH); as sole phosphate binder. Niercnkr Hochdruekkr 1993;22:39-44.
60. Almond VI K. Kwan JTC. Evans K. Cunningham: Loss of regional bone mineral density in the first 12 months following renal transplantation, Nephron 1994;66:52-57.